Today we're updating our outlook for global markets and providing ideas to profit in the second half of 2019.

Part 1 of this playbook will provide our perspective on all four asset classes and update our views on the major themes within India that we're paying attention to.

Part 2 of this playbook will consist of our top individual stock trade ideas.

Today we're updating our outlook for global markets and providing ideas to profit in the second half of 2019.

Part 1 of this playbook will provide our perspective on all four asset classes and update our views on the major themes within India that we're paying attention to.

Part 2 of this playbook will consist of our top individual stock trade ideas.

Today we're exploring opportunities in two beaten-down sectors that look ripe for a squeeze.

Late last week we discussed the structural breakout in Larsen & Toubro, so today we want to look into the entire sector to see what other opportunities there are among its components.

In this post, we're going to outline the most significant charts/updates since April's post.

We've spoken about the lack of trend in the Major Indexes for a while now, but another theme that's becoming more and more pervasive is the weakness in Tech stocks.

Let's see how we're going to approach it.

When trading against the primary trend, there are a few things we look for to define our risk and raise our probability of success.

We outlined them in a post a while back, but they essentially boil down to the following:

1. Our downside price target has been met.
2. Prices undercut that price target and quickly reversed.
3. Momentum diverged positively as prices made a new low.
4. Prices are very extended from their mean (200-day moving average).
5. Quick follow-through confirmed the supply/demand imbalance.
6. Short interest in the stock (not required, but amplifies move).

We are now seeing a few potential opportunities given that stocks have been hit, some harder than others, over the last few weeks.

Here's Reliance Infrastructure quickly reversing off our downside price objective near 100.30 as momentum diverges. As long...

The Pharma Sector had been improving from a structural perspective, but recent action and breadth may be suggesting the space is falling ill again.

Let's examine the evidence.

Yesterday we got new Monthly Candlesticks, so this post will outline a few of the major changes since last month.